Hims & Hers shares declined as analysts warned that aggressive spending on weight-loss drugs is compressing profit margins, prompting a trimmed earnings outlook despite raised revenue forecasts.
reuters · 2026-08-11 04:21
Hims & Hers raised its full-year revenue guidance to $3.1–$3.3 billion after reporting $753 million in quarterly revenue. The growth was driven by a partnership with Novo Nordisk to offer the FDA-appr
reuters · 2026-08-10 13:10
PPG Industries and PepsiCo advanced on better-than-expected earnings, while Hims & Hers climbed after FDA updates on peptide restrictions were announced.
bloomberg · 2026-04-16 04:55
ChemBrief